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bstract
bjective:  In this prospectively planned interim-analysis, the prevalence of chronic obstructive lung disease (COPD) phenotypes was determined
sing magnetic resonance imaging (MRI) and X-ray computed tomography (CT) in non-small-cell-lung-cancer (NSCLC) patients.
aterials  and  methods:  Stage-III-NSCLC patients provided written informed consent for pulmonary function tests, imaging and the 6-min-
alk-test. Ventilation defect percent (VDP) and CT lung density (relative-of-CT-density-histogram <−950, RA950) were measured. Patients were
lassified into three subgroups based on qualitative and quantitative COPD and tumour-specific imaging phenotypes: (1) tumour-specific ventilation
efects (TSD), (2) tumour-specific and other ventilation defects without emphysema (TSDV), and, (3) tumour-specific and other ventilation defects
ith emphysema (TSDVE).
esults:  Seventeen stage-III NSCLC patients were evaluated (68 ±  7 years, 7 M/10 F, mean FEV1 = 77%pred) including seven current and 10
x-smokers and eight patients with a prior lung disease diagnosis. There was a significant difference for smoking history (p  = .02) and FEV1/FVC
p  = .04) for subgroups classified using quantitative imaging. Patient subgroups classified using qualitative imaging findings were significantly
ifferent for emphysema (RA950, p  < .001). There were significant relationships for whole-lung VDP (p  < .05), but not RECIST or tumour-lobe
DP measurements with pulmonary function and exercise measurements. Preliminary analysis for non-tumour burden ventilation abnormal-
ties using Reader-operator-characteristic (ROC) curves reflected a 94% classification rate for smoking pack-years, 93% for FEV1/FVC and
2% for RA950. ROC sensitivity/specificity/positive/negative likelihood ratios were also generated for pack-years, (0.92/0.80/4.6/0.3), FEV1/FVC
0.92/0.80/4.6/0.3), RA950 (0.92/0.80/4.6/0.3) and RECIST (0.58/0.80/2.9/1.1).
onclusions:  In this prospectively planned interim-analysis of a larger clinical trial, NSCLC patients were classified based on COPD imaging
henotypes. A proof-of-concept evaluation showed that FEV1/FVC and smoking history identified NSCLC patients with ventilation abnormalities
ppropriate for functional lung avoidance radiotherapy.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
http://creativecommons.org/licenses/by-nc-nd/4.0/).
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.  IntroductionThe current standard of care for patients with non-small cell
ung cancer (NSCLC) relies on radiation therapy that focuses
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he radiation dose to the tumour, sparing healthy lung tissue.
owever, the current standard approach for radiation therapy
lanning uses four-dimensional computed tomography (4DCT)
o delineate the target volume and this does not take into account
ung function heterogeneity. This is an important consideration,
specially in ex-smokers with chronic obstructive pulmonary
isease (COPD) or other underlying lung disease. In these
atients, pulmonary functional imaging has been used to char-
cterize large functional deficits of poorly and unventilated lung
1,2] which is typically very spatially heterogeneous. Moreover,
is an open access article under the CC BY-NC-ND license
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uch functional defects cannot be easily predicted by smoking
istory or other pulmonary function measurements, including
he forced expiratory volume in 1 second (FEV1) [1,3,4]. Ide-
lly, radiation treatment planning should derive improvements
rom pulmonary imaging measurements that differentiate the
unctioning from non-functioning lung, with attention focused
n the non-functioning part of the lung, independent of tumour
urden.
Pulmonary functional imaging methods such as single pho-
on emission computed tomography (SPECT) [5,6], 4DCT [7,8]
nd inhaled gas magnetic resonance imaging (MRI) [9,10], have
een previously incorporated in functional imaging lung avoid-
nce schemes, but this approach is not currently the standard
linical practice. The feasibility of function-based intensity
odulated radiation therapy (IMRT) treatment planning [5,6,9],
as been demonstrated, in addition to measurements of lung
unction before and after radiation treatment [7,11]. Impor-
antly, when functional imaging was used to guide therapy
n radiation planning studies, dose reductions to functioning
ung were achievable [6,10]. Previous work also identified
hat functional lung avoidance plans can be optimized in
atients with bullous lung disease and large perfusion defects
12,13].
While these thoracic imaging techniques provide a way to dif-
erentiate between functioning and non-functioning lung, there
re a number of inherent limitations that have restricted the
se of functional imaging for radiation therapy planning. For
xample, with SPECT imaging, artefacts stemming from radi-
labelled tracers are typically observed in the major airways
14]. For 4DCT [15], lung function is indirectly measured over
 time series of breaths and the resultant lung function maps
equire extensive image processing that is highly dependent on
eformable image registration [16,17]. Fourier-decomposition
D MRI is an alternative imaging method that indirectly meas-
res lung ventilation and perfusion and correlates well with
ther pulmonary functional MR methods [18]. On the other
and, hyperpolarized noble gas MRI, although very sensitive
o functional ventilation abnormalities, is limited because of its
eliance on specialized MRI and polarization equipment. While
he global quantities of 3He are very limited and expensive,
mpeding its clinical uptake and translation, the sensitivity of this
ethod may guide the use of other MR methods (e.g. Fourier
ecomposition, 129Xe MRI, etc.). In addition, although MRI
ethods are well-tolerated, making them ideal for serial stud-
es [19], until now, these methods have been limited to research
pplications only.
Therefore, in an interim analysis of a larger clinical trial
20], the objective of this proof-of-concept evaluation was
o quantify imaging phenotypes of COPD in patients with
SCLC prior to concurrent chemo- and radiation therapy. We
imed to determine the utility of conventional and clinically
vailable COPD measurements in stratifying patients for func-
ional lung avoidance radiotherapy. We hypothesized that COPD
henotypes could be used to stratify NSCLC patients prior
o radiotherapy planning as a first step towards personalizing
reatment plans based on lung structural and functional mea-
urements.
d
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.  Materials  and  methods
.1.  Study  participants
Study participants were evaluated in a prospectively planned
nterim analysis of a clinical trial in over 60 patients [20].
he logistical details of this clinical trial (NCT02002052)
ere previously published [20]; here we provide an interim
nalysis of the feasibility of acquiring and quantifying MRI
henotypes prior to randomization to standard or individual-
zed functional lung avoidance radiation treatment. Volunteers
ith histologically confirmed non-resectable Stage IIIA or IIIB
SCLC and a smoking history of >10 pack-years provided
ritten informed consent to this randomized controlled clini-
al trial which complied with the Health Insurance Portability
nd Accountability Act (HIPAA) and Personal Information Pro-
ection and Electronic Documents Act (PIPEDA), and approved
y our local research ethics board and by Health Canada. Briefly,
ll subjects were required to be over 18 years of age, with
n Eastern Cooperative Oncology Group (ECOG) performance
core between 0 and 2, FEV1 > 30%pred, and able to undergo
latinum-based chemotherapy as determined by his/her treat-
ng physicians. Those subjects with contradictions to the MRI
i.e. metal/electronic/magnetic implants, claustrophobia, etc.),
erious co-morbidities, prior thoracic radiation, metastatic dis-
ase, or conflicts with routine radiotherapy were not considered
uitable for the study. In addition to routine clinical care, in a
wo and a half hour visit, all study volunteers underwent addi-
ional pulmonary function tests, MRI, one additional low dose
nspiratory CT, and the 6 min walk test (6MWT) [20].
.2.  Pulmonary  function  tests
Spirometry was used to acquire the forced expiratory vol-
me in one second (FEV1), forced vital capacity (FVC),
nd FEV1/FVC according to American Thoracic Society
ATS) guidelines (Medgraphics Elite Series Plethysmograph,
edGraphics Corporation, St. Paul, MN, USA) [21]. Body
lethysmography was also performed to measure lung volumes
nd the diffusing capacity of carbon monoxide (DLCO) was also
easured using the attached gas analyser (Medgraphics Elite
eries Plethysmograph).
.3.  Image  acquisition
MRI was acquired in the coronal plane using a whole body
.0 Tesla Discovery MR750 (General Electric Health Care,
ilwaukee, WI) system with broadband imaging capability.
olarization of the 3He/129Xe gas was performed using a
olarizer system (HeliSpin/XeniSpin; Polarean, Durham,
C, USA) and achieved polarization levels of approximately
0%/8%. Hyperpolarized 3He was diluted with medical-
rade N2 gas (Spectra Gases, NJ, USA) and 129Xe was
4 ®iluted with He/N2 and administered in 1.0-L Tedlar bags
Jensen Inert Products, FL, USA). Subjects were instructed
o inhale a gas mixture from the bag from functional residual
apacity (FRC) and image acquisition was performed under
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reath-hold conditions [22]. 1H MRI was acquired with subjects
n breath-hold using a whole-body radiofrequency coil and
1H fast spoiled gradient-recalled echo (FGRE) sequence
ith a partial echo (16 s total data acquisition, repetition time
TR]/echo time [TE]/flip angle = 4.7 ms/1.2 ms/30◦, field-of-
iew [FOV] = 40 cm ×  40 cm, bandwidth [BW] = 24.4 kHz,
atrix = 128 ×  80, 15–17 slices, 15 mm slice thickness, 0 gap),
s previously described [22]. Hyperpolarized 3He MRI static
entilation imaging was performed using a 2D multi-slice fast
radient-recalled echo sequence with a partial echo (total data
cquisition time = 10 s; TR/TE/flip-angle = 3.8 ms/1.0 ms/7◦;
OV = 40 cm ×  40 cm; matrix = 128 × 80; BW = 62.50 kHz;
umber of excitations [NEX] = 1; number of slices = 16; slice
hickness = 15 mm) during breath hold [22]. Hyperpolarized
29Xe MRI static ventilation imaging was performed to
etermine whether it provided similar or additional information
o 3He MRI. 129Xe MRI was performed using a 3D FGRE
equence (total data acquisition time = 16 s; TR/TE/flip-
ngle = 7.0 ms/1.8 ms/variable; FOV = 40 cm ×  40 cm; matrix =
28 ×  128; BW = 9 kHz; NEX = 1; number of slices = 16; slice
hickness = 15 mm) during a breath-hold. The time duration
etween 3He and 129Xe was 10–15 min. The subject was
emoved from the bore of the MRI to allow for the coils to be
witched. The subject was re-localized, 1H MRI was performed
ollowed by 129Xe MRI.
Thoracic CT images were acquired at FRC + 1 L using
 multi-detector, 64-slice Lightspeed VCT scanner (General
lectric Health Care, Milwaukee, WI) (64 mm ×  0.625 mm
ollimation, 120 kVp, 100 effective mA, tube rotation
ime = 500 ms, pitch = 1.0) [23]. A spiral acquisition was used
nd images reconstructed using a standard convolution kernel
o 1.25 mm [23].
.4.  Image  analysis
Noble gas static ventilation images were segmented and reg-
stered to the 1H MRI thoracic cavity using custom software
e previously generated using MATLAB R2014a (Mathworks,
atrick, MA, USA), as previously described [24]. Ventilation
bnormalities were quantified using the ventilation defect per-
ent (VDP) which represents the volume of ventilation defects
VDV) normalized to the thoracic cavity volume (TCV). Briefly,
He static ventilation images were segmented by a single
bserver (K.S. with three years of experience performing semi-
utomated segmentation and a coefficient of variation of 4%)
sing a k-means approach that classified voxel intensity val-
es into five clusters ranging from signal void (cluster 1[C1]
r VDV) and hypo-intense (cluster 2 [C2]) to hyper-intense
ignal (cluster 5 [C5]), therefore, generating a gas distribution
luster-map. For delineation of the ventilation defect bound-
ries, a seeded region-growing algorithm was used to segment
he 1H MRI thoracic cavity for registration to the cluster-map,
s previously described [24].
Pulmonary Workstation 2.0 (VIDA Diagnostics Inc.,
oralville, IA, USA) was used to quantify the relative area of
he CT density histogram with attenuation values <−950 HU
p
Y
t
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RA950) as well as segmenting the lungs and lobes. Using the
ulmonary lobe masks produced by VIDA, the VDP for each
ulmonary lobe was determined by applying these masks to the
tatic ventilation images. Ventilation defect percent was calcu-
ated for the tumour lobe(s) (VDPTL) and the lobes with no
umour (VDPNTL). VDPTL was generated by normalizing the
entilation defect volume for a specific lobe to the corresponding
obe volume. Similarly, the VDPNTL was generating by normal-
zing the ventilation abnormalities of the non-tumour lobe(s)
o the corresponding lobar volume(s). Finally, the Response
valuation Criteria in Solid Tumours (RECIST) was evaluated
25].
Subjects were classified into three sub-groups based on qual-
tative and quantitative imaging evidence of ventilation defects
nd emphysema: (1) subjects with tumour-specific ventilation
efects (TSD), (2) subjects with tumour-specific and other venti-
ation defects with no emphysema (TSDV), and, (3) subjects with
umour-specific and other ventilation defects with emphysema
TSDVE). Three observers ((a) G.P. with 10 years of experience,
b) K.S. with three years of experience, and (c) D.P.I.C. with
wo years of experience analyzing noble gas MRI and CT) in
 consensus decision, qualitatively evaluated and classified all
ubjects based on the visible evidence of tumour and non-tumour
obe ventilation defects and on the presence of emphysema. For
ualitative analyses, all image slices were evaluated using 3D
licer 4.2 open-source platform (http://www.slicer.org, Boston,
A) as the visualization environment and with flexible win-
ows and levels for ventilation and emphysema extent. For
uantitative classification of subjects, the upper limit of the
5% confidence interval of VDP measurements from a pre-
iously published [26] study in healthy volunteers was used
s the threshold (>3%) for ventilation defects. Subjects with
entilation defects in the tumour lobe only (non-tumour lobes:
DP < 3%) were classified in the TSD subgroup. Subjects with
entilation defects in non-tumour lobes (VDP > 3%) were classi-
ed in the TSDV subgroup. For those subjects with non-tumour
obe ventilation defects, the value of RA950 ≥  5% was used
o further stratify these subjects into the TSDVE subgroup
27].
.5.  Statistical  analysis
A one-way analysis of variance (ANOVA) with post hoc
ukey HSD (Honest Significant Differences) and Pearson cor-
elation coefficients (r) were used to determine the relationships
etween measurements using SPSS Statistics V22.0 (SPSS Inc.,
BM Corporation, Armonk, NY, USA). Results were consid-
red significant when the probability of two-tailed type I error
) was less than 5% (p  < .05). Receiver-operating characteris-
ic (ROC) curves were used to characterize the performance
f pulmonary function test and other clinical measures as
redictors of the presence of ventilation defects not asso-
iated with tumour burden (control group: TSD sub-group;
atient group: TSDV and TSDVE sub-groups). The maximum
ouden’s J index value (J = sensitivity + specificity-1) was used
o determine the optimum cut-off point and the corresponding
ensitivity, specificity, positive and negative likelihood ratios
84 K. Sheikh et al. / European Journal of Radiology Open 2 (2015) 81–89
Fig. 1. 3He MRI and CT for representative subjects with tumour-specific ventilation defects (TSD), tumour-specific and other ventilation defects (TSDV), without
emphysema, and tumour-specific and other ventilation defects with emphysema (TSDVE) based on quantitative analysis. Left: 3He MRI coronal static ventilation in
b 1 tion <
c and C
l  reade
w
n
o
2
G
U
3
3lue co-registered to H MRI. Middle: CT density masks where yellow = attenua
lusters (LAC), represented as spheres with CT densitometry values <−950 HU 
ocation. (For interpretation of the references to colour in this figure legend, the
ere calculated. It should be noted that to demonstrate a sig-
ificant Reader Operator curve result with the same number
f positive and negative cases, the required sample size is
6 [28]. The ROC analysis statistics were performed using
raphPad Prism version 6.02 (GraphPad, Inc., San Diego, CA,
SA). c −950 Hounsfield units (RA950). Right: CT three-dimensional low-attenuation
T three-dimensional reconstruction airway tree. Yellow arrows indicate tumour
r is referred to the web version of this article.)
.  Results
.1.  ParticipantsTwenty-three subjects consented to the study, but only 17
ompleted MRI and pulmonary function tests (PFTs) and were
K. Sheikh et al. / European Journal of Radiology Open 2 (2015) 81–89 85
Table 1
Subject listing and classification.
Sex Age (y) Pack-years Current smoker Tumour
location
Previously diagnosed
lung disease
Quantitative
classification
Qualitative classification
001 F 62 50 N RLL COPD TSDVE TSDVE
002 F 69 50 N LLL COPD TSDVE TSDVE
003 M 67 50 N RUL None TSDV TSDV
004 F 68 35 N RUL COPD TSD TSDV
006 M 71 50 Y LUL COPD TSDVE TSDVE
007 F 63 50 Y RUL None TSDV TSDV
008 F 70 45 Y RUL None TSD TSD
010 F 65 35 N RML None TSDV TSDV
011 F 56 42 Y LLL COPD TSDV TSDV
012 M 72 50 N LLL COPD TSDVE TSDVE
013 F 62 10 N RUL None TSD TSDV
015 F 79 30 Y LLL None TSD TSDV
017 F 67 30 N RUL Asthma TSD TSDV
019 M 68 53 Y RUL None TSDV TSDV
020 M 59 40 N RML None TSDVE TSDVE
021 M 81 70 N LUL None TSDV TSDV
023 M 74 90 Y LUL COPD TSDV TSDV
Mean 7 M/10 F 68 46 7 Y/10 N 7 COPD/
1 Asthma/
9 none
5 TSD/
7 TSDV/
5 TSDVE
1 TSD/11 TSDV/5 TSDVE
R  = lef
o ; TSD
i
d
o
T
7
t
b
j
N
c
(
l
e
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aLL = right lower lobe; RUL = right upper lobe; RML = right middle lobe; LLL
nly; TSDV = tumour-specific and other ventilation defects with no emphysema
ncluded in this analysis. The six subjects who consented but
id not complete evaluations were unable to participate because
f difficulties in travel conditions to the site (snowstorm).
able 1 shows a subject listing for the 17 subjects (68 ±  7 years,
 M/10 F) who completed baseline imaging and pulmonary func-
ion measurements and participant classification according to
oth qualitative and quantitative imaging phenotypes. All sub-
ects were diagnosed with locally advanced Stage IIIA or IIIB
SCLC according to the American Joint Committee on Can-
er (7th edition) [29] with a smoking history of >10 pack-years
46 ±  17 pack-years). Of the 17 subjects who completed base-
ine measurements, seven were current smokers and ten were
x-smokers with a mean years-quit of 16 ±  13 years. Eight sub-
ects had a prior diagnosis of lung disease. Nine patients reported
EV1/FVC < 70% and four patients reported FEV1 < 50%pred.
.2.  Imaging  and  other  measurements  by  subgroup
Fig. 1 shows the coronal 3He static ventilation image with the
orresponding RA950 map, CT low attenuation cluster (LAC)
ap and the airway tree for six representative subjects, includ-
ng: (1) S4 and S17 with quantitative tumour-specific ventilation
efects only, (2) S3 and S19 with quantitative tumour-specific
nd other ventilation defects, and, (3) S2 and S6 with quantita-
ive tumour-specific and other ventilation defects with comorbid
mphysema. Yellow arrows show the location of tumour masses.
pecifically, subjects S4 and S17 in the TSD subgroup showed
omogeneous regions of ventilation, except for the regions
ear the tumour, where obvious ventilation abnormalities were
learly visible. Qualitatively, these two subjects also showed
ore complete airway trees than those subjects in the TSDV and
SDVE subgroup. Subjects in the TSDV and TSDVE subgroups
s
r
Ft lower lobe; LUL = left upper lobe; TSD = tumour-specific ventilation defects
VE = tumour-specific and other ventilation defects with emphysema.
ad numerous and large ventilation defects related to the tumour
nd also in non-tumour regions of interest. For the two repre-
entative participants (S2 and S6) in the TSDVE subgroup there
as visible evidence of significant centrilobular emphysema as
eflected in the RA950 and low attenuating cluster maps.
Table 2 shows subject demographics, pulmonary function
nd 6MWT measurements for all participants and the three
ualitative and quantitative comparator subgroups. There were
o significant differences among the qualitatively determined
ubgroups, except for RA950 (p  < .001). In the quantitatively
etermined subgroups, there were significant differences for
EV1/FVC (p  = .04) and smoking history (p  = .02). Post hoc
nalysis showed that the TSDV subgroup had significantly dif-
erent FEV1/FVC (p  = .04), and smoking history (p  = .02) than
he TSD subgroup.
.3.  Univariate  relationships
As shown in Table 3 for all measurements and in detail in
ig. 2, there were significant relationships for whole lung VDP
ith pulmonary function (FEV1, FEV1/FVC, IC, and FRC),
LCO, 6MWD, and pre-6MWT oxygen saturation measure-
ents but not RECIST or RA950 measurements. For tumour-lobe
DP, there was a significant relationship with pre-6MWT SpO2
hile for non-tumour-lobe VDP there was a significant rela-
ionship with pulmonary function measurements (FEV1/FVC
nd FRC). Finally, RA950 was significantly related to FRC
nd the longest tumour diameter RECIST measurement was
ignificantly related to VDPTL. Fig. 2 shows the significant
elationships for VDP with SpO2, VDPNTL with FRC and
EV1/FVC and finally RA950 with FRC.
86 K. Sheikh et al. / European Journal of Radiology Open 2 (2015) 81–89
Table 2
Subject demographics, pulmonary function test, and imaging measurements.
Mean (±SD) All Quantitative classification Qualitative classification
(n = 17) TSD TSDV TSDVE p-value TSD TSDV TSDVE p-value
(n = 5) (n = 7) (n = 5) (n = 1) (n = 11) (n = 5)
Age yrs 68 (7) 69 (6) 68 (8) 67 (6) .9 70 68 (7) 67 (6) .9
Male n 7 0 4 3 – 0 4 3 –
BMI kg/m2 28 (4) 27 (4) 29 (4) 28 (6) .8 25 28 (4) 28 (6) .8
Pack years 46 (17) 30 (13) 56 (19) 48 (4) .02 45 45 (22) 48 (4) ∼1
Lung disease n 8 2 2 4 – 0 4 4 –
RECIST mm 49 (22) 54 (21) 40 (25) 57 (18) .4 90 42 (20) 57 (18) .07
FEV1%pred 77 (28) 94 (14) 68 (27) 72 (36) .3 77 79 (26) 72 (36) .9
FEV1/FVC % 65 (10) 75 (3) 61 (8) 62 (13) .04 71 66 (10) 62 (13) .7
IC %pred 86 (22) 100 (20) 83 (21) 76 (22) .2 113 88 (21) 76 (22) .3
FRC %pred 116 (27) 97 (10) 117 (27) 134 (30) .08 105 109 (24) 134 (30) .2
DLCO %pred 55 (18) 57 (20) 60 (13) 45 (22) .4 46 60 (16) 45 (22) .3
SpO2% 95 (5) 98 (2) 95 (5) 91 (8) .2 98 96 (4) 91 (8) .2
6MWD m 355 (77) 372 (78) 360 (47) 331 (115) .7 313 370 (59) 331 (115) .6
VDP % 13 (10) 7 (4) 13 (11) 20 (9) – 13 10 (10) 19 (9) .3
VDPTL % 26 (24) 23 (25) 17 (13) 41 (32) – 60 16 (14) 41 (32) .05
VDPNTL % 8 (9) 1 (1) 10 (12) 12 (8) – 1 7 (10) 12 (8) .5
RA950% 4 (4) 1 (1) 1 (1) 9 (3) – 1 1 (1) 9 (3) <.001
Bold values represent significant differences.
TSD = tumour-specific ventilation defects only; TSDV = tumour-specific and other ventilation defects with no emphysema; TSDVE = tumour-specific and other
ventilation defects with emphysema; Sig Dif = Significant difference between subgroups (p < .05) determined by ANOVA; SD = standard deviation; %pred = percent
predicted; BMI = body mass index; Lung disease = previously diagnosed lung disease; RECIST = Response Evaluation Criteria in Solid Tumours baseline longest
diameter; FEV1 = forced expiratory in 1 s; FVC = forced vital capacity; IC = inspiratory capacity; FRC = functional residual capacity; DLCO = diffusing capacity
of carbon monoxide; SpO2 = pre-6MWT digital oxygen saturation value 6MWT = 6 min walk test; 6MWD = distance travelled in 6 min; VDP = ventilation defect
percent; TL = tumour lobe; NTL = non-tumour lobes; RA950 = relative area of the lung with attenuation values <−950 HU.
Table 3
Univariate relationships between imaging measurements and pulmonary function, smoking history, and 6MWT measurements.
VDPr (p-value) VDPNTLr (p-value) VDPTLr (p-value) RA950r (p-value) RECISTr (p-value)
FEV1%pred −0.58 (.02) −0.47 (.06) −0.25 (.3) −0.06 (.8) −0.10 (.7)
FEV1/FVC % −0.51 (.04) −0.73 (.001) −0.07 (.8) −0.33 (.2) −0.12 (.7)
IC %pred −0.64 (.01) −0.45 (.07) −0.30 (.3) −0.17 (.2) −0.03 (.9)
FRC %pred 0.51 (.04) 0.74 (.001) 0.19 (.5) 0.50 (.04) 0.003 (.9)
DLCO %pred −0.54 (.03) −0.11 (.7) −0.46 (.06) −0.28 (.3) −0.27 (.3)
SpO2% −0.71 (.001) −0.34 (.2) −0.56 (.02) −0.30 (.3) −0.32 (.2)
6MWD m −0.50 (.04) −0.05 (.8) −0.48 (.05) −0.07 (.8) −0.18 (.5)
Pack−years yr 0.34 (.2) 0.25 (.3) 0.13 (.6) 0.16 (.5) 0.29 (.3)
VDPTL % 0.59 (.01) 0.16 (.5) – 0.10 (.7) 0.53 (.03)
Bold values represent significant correlations.
V lobe;
R 2 = p
3
m
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F
0DP = ventilation defect percent; NTL = non-tumour lobes; TL = tumour 
ECIST = Response Evaluation Criteria in Solid Tumour longest diameter; SpO
.4.  ROC  analysis
In Fig. 3, we evaluated a number of different measure-
ents as discriminants of patients with and without ventilation
bnormalities beyond the tumour region-of-interest using ROC
urves. FEV1/FVC and pack-years were evaluated because
hese two measurements were significantly different for the
uantitatively determined subgroups. RA950 was also evalu-
ted in order to ascertain the role of underlying emphysema
n discriminating patients. Tumour RECIST measurements
ere also evaluated because these measurements are com-
only used to reflect tumour burden. Pack-years (AUC = 0.94,
5% CI = 0.83–1.06, p  = .005), FEV1/FVC (AUC = 0.93, 95%
I = 0.82–1.05, p = .006) and RA950 (AUC = 0.82, 95%
4
s RA950 = relative area of the lung with attenuation values <−950 HU;
re-6MWT digital oxygen saturation value; 6MWD = 6 min walk distance.
I = 0.58–1.06, p  = .04) significantly discriminated NSCLC
atients with additional non-tumour specific ventilation defects,
ut RECIST measurements (AUC = 0.60, 95% CI = 0.32–0.88,
 = .5) did not. Furthermore, for each diagnostic measurement,
he established cut-off point and the corresponding performance
haracteristics (sensitivity, specificity, positive and negative like-
ihood ratios) were: pack-years: >37.5 years, 0.92, 0.80, 4.6, 0.3;
EV1/FVC: <73.5%, 0.92, 0.80, 4.6, 0.3; RA950: >1.15%, 0.92,
.80, 4.6, 0.3; RECIST: <45.5 mm, 0.58, 0.8, 2.9, 1.1..  Discussion
To better understand the feasibility of pulmonary imaging
tructure–function phenotyping of patients prior to radiation
K. Sheikh et al. / European Journal of Radiology Open 2 (2015) 81–89 87
Fig. 2. Univariate relationships for imaging measurements and other measurements. (A) VDP and SpO (r = −0.71, p = .001), (B) VDP and FEV /FVC (r = −0.73,
p = .001), (C) VDPNTL and FRC (r = 0.74, p = .001), and, (D) RA950 and FRC (r = 0.50,
lines.
Fig. 3. Receiver-operating characteristic curves for the identification of ventila-
tion defects not associated with the tumour using pack-years (black solid line),
FEV1/FVC, (dark grey solid line), RA950, (black dashed line), and RECIST
longest diameter (dark grey dashed line). The area under the curve, [95%
confidence interval], (p-value) were: pack-years = 0.94, [0.83–1.06] (p = .005);
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pEV1/FVC = 0.93 [0.82–1.05], (p = .006); RA950 = 0.82, [0.58–1.05], (p = .04),
nd; RECIST = 0.60, [0.32–0.88], (p = .5).
herapy planning, we evaluated 17 Stage III NSCLC subjects
ased on regional ventilation heterogeneity and emphysema
easurements before their radiation therapy plans were for-
ulated. We made a number of observations including: (1)
hree different subgroups were quantitatively and qualitatively
dentified based on the presence of tumour-specific ventilation
t
i2 NTL 1
 p = .04). The dotted lines represent the 95th confidence interval of the regression
bnormalities, and COPD-biomarkers such as non-tumour ven-
ilation abnormalities and emphysema, (2) for quantitatively
dentified subgroups, there were significant differences for pack-
ears and FEV1/FVC, but not tumour RECIST measurements,
nd for qualitatively identified subgroups, there was a significant
A950 difference, (3) whole lung and non-tumour lobe VDP
ere significantly correlated with pulmonary function test mea-
urements, but tumour lobe VDP and RECIST measurements
ere not, and, (4) ROC analysis identified smoking pack-years,
EV1/FVC, and RA950 as diagnostics for non-tumour burden
maging findings reflective of COPD.
We used quantitative pulmonary imaging to classify patients
ased on the extent of underlying COPD and independent of
ulmonary function tests. Three different subgroups were iden-
ified and it was somewhat unexpected that not all NSCLC
atients with a previous diagnosis of asthma or COPD exhib-
ted the ventilation heterogeneity commonly observed in COPD
ubjects [1,2]. The premise of functional lung avoidance radia-
ion therapy is the specific targeting of regional non-functioning
ung, so subjects with no ventilation heterogeneity would not
e good candidates for this approach, as previously described
sing SPECT perfusion imaging [13]. This finding has had a
rofound effect on our original plan to randomize all NSCLC
atients to either standard or individualized radiation therapy
lanning because only a subgroup of patients exhibited COPD
henotypes such as ventilation heterogeneity and emphysema
hat could be used in the radiation treatment planning process.
We also evaluated the practicality of using qualitative  imag-
ng phenotypes of COPD and noted that the composition of the
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hree subgroups was markedly different with respect to patients
ith tumour-specific and other defects. These results can be
xplained by the semi-automated segmentation tool used for
uantitative analysis of noble gas MRI ventilation. As previ-
usly described [24], an expert observer can distinguish between
our visually different classes of 3He MRI gas signal includ-
ng: signal void, hypointense regions, normal intensity, and
yperintense signal [24]. Quantitative segmentation depends on
-means clustering that identifies two distinct clusters (signal
oid and hypointense clusters), but visually, these regions appear
s signal void. Therefore patients with visibly obvious ventila-
ion defects may not meet the threshold for ventilation defect
ercent. This is evident by the fact that there were more sub-
ects with qualitatively as compared to quantitatively identified
entilation defects. Regardless, for the two different types of
ubgroups, there were no significant differences observed for
ulmonary function, 6 min walk test or MRI measurements,
lthough emphysema (RA950) was significantly different. These
esults lead us to believe that ventilation defects may be due to
 combination of small airway occlusion, mucous plugs, airway
all thickening and inflammation or bullous disease, which are
ommon in COPD [30,31]. These results also suggest that qual-
tative analysis may not be appropriate for phenotyping COPD
atients, supporting the need for quantitative analysis or the use
f novel biomarkers [32] not investigated here.
It is interesting to note that whole lung and non-tumour lobe
DP were significantly correlated with pulmonary function test
easurements, but baseline RECIST measurements and VDPTL
id not. These results are consistent with previous findings which
eported a relationship for increased hyperpolarized gas MRI
entilation heterogeneity with poor lung function and exercise
apacity in COPD [1,33]. To determine if the diminished pul-
onary function observed in these subjects was due to tumour
urden or the underlying COPD, we determined the relation-
hips for VDP in the tumour lobe and non-tumour lobes. The
act that VDP in the non-tumour lobes was related to pulmonary
unction test measurements reinforces the notion that tumour
urden alone does not explain airflow and exercise limitation in
SCLC subjects.
Finally, among the three quantitatively identified subgroups,
here were significant differences for smoking history (pack-
ears) and FEV1/FVC, but not for exercise capacity or tumour
ECIST measurements. This supports the idea that the air-
ow limitation observed in NSCLC patients is contributed
y a combination of the tumour burden, airways disease and
mphysema, similar to what was previously observed in COPD
ubjects [1,34]. Importantly, ROC analysis estimated a classi-
cation rate of 94% for pack-years and 93% for FEV1/FVC
hen discriminating patients based on COPD imaging phen-
types. Smoking history measured in pack-years, as well as
EV1/FVC, and RA950 showed 92% sensitivity (true posi-
ives) and 80% specificity (true negatives). The likelihood
atios for these diagnostic measurements also suggested that
SCLC patients with a positive test (i.e. pack-years > 37.5 years,
EV1/FVC < 73.5%, RA950 > 1.15%) were approximately five
imes more likely to have COPD-like ventilation abnormalities
s NSCLC patients with a negative test (i.e. pack-years < 37.5
B
a
dRadiology Open 2 (2015) 81–89
ears, FEV1/FVC > 73.5%, RA950 < 1.15%). This strongly sug-
ests that FEV1/FVC, pack-years, and RA950 can be used
s diagnostics for COPD-related ventilation abnormalities in
atients with NSCLC. Although these measures had similar
ensitivity and specificity, the AUC suggested different clas-
ification rates for FEV1/FVC and pack-years (classification
ates of 93% and 94%, respectively) versus RA950 (classifica-
ion rate of 82%). We also acknowledge that the sample size for
he interim ROC analysis was smaller than typically required to
etermine significant predictors, so caution must be used in its
nterpretation and the results should be considered exploratory
nd hypothesis generating. Certainly, once the clinical trial is
ompleted, 64 subjects will be evaluated and the results of the
nterim analysis will help guide recruitment to appropriately test
ur hypotheses.
We recognize that because of the expense and limited quan-
ities of 3He gas, alternative pulmonary imaging methods such
s 129Xe MRI and Fourier decomposition MRI should be opti-
ized and utilized to provide similar lung structure–function
OPD measurements. It is also important to note that these
ubjects were classified based on the presence of ventilation
efects and emphysema without regard to the location of the
umour with respect to the ventilation defects and emphyse-
atous regions. Unfortunately, due to the small sample size in
his study, categorizing these subjects based on tumour location
as not feasible. Future work should incorporate this informa-
ion when phenotyping subjects for functional lung avoidance
adiation therapy.
.  Conclusions
In summary, we classified NSCLC subjects into three
ubgroups based on imaging measurements of ventilation
eterogeneity and the presence of emphysema. In this proof-
f-concept analysis, pulmonary imaging was used to phenotype
SCLC patients on the basis of underlying COPD biomarkers of
irways disease and emphysema. We observed that non-tumour
obe ventilation heterogeneity was related to pulmonary func-
ion test measurements. In addition, smoking history and airflow
imitation independently provided a >93% classification rate
or patients with ventilation abnormalities beyond the tumour
uggesting that these measurements may be used to categorize
SCLC patients for functional lung avoidance radiation therapy
chemes. Taken together these results suggest that COPD phen-
types provide a way to identify NSCLC patients for functional
ung avoidance radiation therapy.
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